IDWeek 2022

Washington DC, US 19 October 2022 - 23 October 2022

Letermovir as good as valganciclovir for CMV prophylaxis

25 Nov 2022 bởi

The novel antiviral letermovir is as good as the current standard of care valganciclovir in preventing cytomegalovirus (CMV) infection in post-kidney transplant patients, but with less toxicity, according to a phase III trial presented at IDWeek 2022.

25 Nov 2022

Early ART yields better outcomes in HIV

14 Nov 2022 bởi

Early antiretroviral therapy (ART) in individuals with HIV offers better outcomes, particularly in those aged 35 years and younger, in a follow-up analysis of the START trial. Conversely, delayed therapy results in a higher risk of death and serious health issues in this population.

14 Nov 2022

Ibrexafungerp: A potential solution for intolerance to standard antifungals?

11 Nov 2022 bởi

Patients who are refractory or intolerant to currently approved antifungal therapies exhibited a positive response to the novel triterpenoid antifungal ibrexafungerp, according to interim analysis results of the phase III FURI trial.

11 Nov 2022

EDS device with fluticasone cuts CRS exacerbations

08 Nov 2022 bởi

The use of an exhalation delivery system with fluticasone (EDS-FLU) significantly reduces acute exacerbations of chronic rhinosinusitis (CRS), which may help drive down the need for antibiotics and prevent antibiotic resistance, in the ReOpen1 and 2 randomized controlled trials.

08 Nov 2022

Carbapenem-sparing cephamycins effective in E coli-induced UTI

28 Oct 2022 bởi

Cefmetazole and cefoxitin prove to be effective in the treatment of patients with urinary tract infections (UTIs) due to extended-spectrum beta-lactamase (ESBL)–producing Escherichia coli, according to two separate studies presented at IDWeek 2022.

28 Oct 2022

COVID-19 worsens antibiotic resistance

28 Oct 2022 bởi

While rare, infection with antibiotic-resistant gram-negative bacteria (AR-GNB) following a positive COVID-19 diagnosis is more severe and often results in worse outcomes, according to a study presented at the recent Virtual ID Week 2022.

28 Oct 2022

Microfluidic PCR platform promises early detection of neonatal sepsis

27 Oct 2022 bởi

A digital microfluidic (DMF) device can reduce time to detect bacteria by as much as 9 hours, speeding up the diagnosis of neonatal sepsis, as shown in a study presented at IDWeek 2022 in Washington, DC, US.

27 Oct 2022

B/F/TAF safe, effective in adults with high HIV-1 RNA, low CD4 count

27 Oct 2022 bởi

Adults with a high baseline HIV-1 RNA or low CD4 count may benefit from initial treatment with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), which has been shown to be safe and efficacious over 5 years of follow-up in a study presented at the ID Week 2022 Virtual Conference.

27 Oct 2022

Ridinilazole triggers clinical response in CDI, inhibits recurrence

27 Oct 2022 bởi

In patients with Clostridioides difficile infections (CDI), treatment with ridinilazole (RDZ) leads to high and sustained rates of clinical response, according to a study presented at the recently concluded Virtual ID Week 2022. Compared with vancomycin (VAN), RDZ also more strongly prevents recurrent CDI (rCDI).

27 Oct 2022

Tenofovir alafenamide reduces liver stiffness in CHB patients

26 Oct 2022 bởi

Treatment with the nucleos(t)ide analogue (NUC) tenofovir alafenamide (TAF) for 2 years leads to improvements in liver stiffness among patients with chronic hepatitis B (CHB), including those with advanced liver fibrosis, according to a study presented at the IDWeek 2022 in Washington, DC, US.

26 Oct 2022